Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease - 21/06/10
Doi : 10.1016/j.gcb.2010.03.009
T.W. H. Pols, J. Auwerx, K. Schoonjans ⁎ 
Laboratory of Integrative and Systems Physiology (LISP), école polytechnique fédérale de Lausanne, 1015 Lausanne, Switzerland
Corresponding author.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Summary |
Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2010
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 34 - N° 4-5
P. 270-273 - Aprile 2010 Ritorno al numero
Articolo precedente
- Human cirrhosis: Monoclonal regenerative nodules derived from hepatic progenitor cells abutting ductular reaction
- P. Bioulac-Sage, C. Balabaud
- Surgical management of liver metastases from gastrointestinal endocrine tumors
- E. Boleslawski, S. Dharancy, S. Truant, F.-R. Pruvot
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.